Phase III Astellas readout marks step forward for non-hormonal menopause therapies

Astellas’ bet on women’s health company Ogeda is paying off with a pair of positive Phase III readouts for its first-in-class, non-hormonal menopause therapy.

Astellas Pharma Inc. (Tokyo:4503) said Friday the Phase III SKYLIGHT 1 and SKYLIGHT 2 trials of fezolinetant met their co-primary endpoints of reducing the frequency and severity of moderate to severe vasomotor symptoms, including hot flashes, associated with menopause at week 4 and week 12. Detailed data will be presented following 52-week analyses. ...